콜린분해효소 억제제의 사용 유무에 따른소혈관성 치매 환자의 임상 경과
Clinical Course of Small Vessel Dementia PatientsAccording to Cholinesterase Inhibitor Treatment
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Small vessel dementia (SVD) is the most frequent cause of vascular dementia and is regarded a distinct clinical entity. However, the data on the natural course of SVD and drug trials specifically aiming SVD have been sparse. The aim of this study was to answer the following three questions: 1) How does SVD progress? 2) Does cholinesterase inhibitor therapy improves cognitive symptoms and daily activity of life (ADL) in SVD? 3) Is there any clinical difference among the subtypes of SVD? Methods: According to cholinesterase inhibitor medications, patients with SVD were retrospectively analyzed using Hyoja Dementia registry. In this study, effects of treatment were assessed by comparing the scores of Korea version Mini-Mental State Examination (MMSE), Clinical Dementia Rating scale (CDR), Functional Independence Measure (FIM) at the base line with those at endpoints. Results: After 12 months, the mean MMSE, CDR, FIM scores improved significantly in the cholinesterase inhibitor treatment group, compared with that in no-treatment group. In no-treatment group, annual decline of MMSE was 2.7, compared with 0.3 increment in the treatment group. White matter type of SVD showed worst prognosis compared with other types. Conclusions: This study suggests that SVD has more benign clinical course than previously reported, and cholinesterase inhibitor improves cognitive and ADL functions in SVD. Among the subtypes of SVD, the white matter type may have poor prognosis.
Abstract
Background: Small vessel dementia (SVD) is the most frequent cause of vascular dementia and is regarded a distinct clinical entity. However, the data on the natural course of SVD and drug trials specifically aiming SVD have been sparse. The aim of this study was to answer the following three questions: 1) How does SVD progress? 2) Does cholinesterase inhibitor therapy improves cognitive symptoms and daily activity of life (ADL) in SVD? 3) Is there any clinical difference among the subtypes of SVD? Methods: According to cholinesterase inhibitor medications, patients with SVD were retrospectively analyzed using Hyoja Dementia registry. In this study, effects of treatment were assessed by comparing the scores of Korea version Mini-Mental State Examination (MMSE), Clinical Dementia Rating scale (CDR), Functional Independence Measure (FIM) at the base line with those at endpoints. Results: After 12 months, the mean MMSE, CDR, FIM scores improved significantly in the cholinesterase inhibitor treatment group, compared with that in no-treatment group. In no-treatment group, annual decline of MMSE was 2.7, compared with 0.3 increment in the treatment group. White matter type of SVD showed worst prognosis compared with other types. Conclusions: This study suggests that SVD has more benign clinical course than previously reported, and cholinesterase inhibitor improves cognitive and ADL functions in SVD. Among the subtypes of SVD, the white matter type may have poor prognosis.
참고문헌 (28)
- Inzitari D, "Subcortical vascular dementia as a specific target for clinical trials", Ann NY Acad Sci, 903, pp.510~521 (2000)
- Pantoni L, "Pathophysiology of cerebral small vessels in vascular cognitive impairment", Int Psychogeriatr, 15(1), pp.59~65 (2003)
- Launer LJ, "Epidemiology of white-matter lesions", Int Psychogeriatr, 15(1), pp.99~103 (2003)
- de Leeuw FE, "Hypertension and cerebral white matter lesions in a prospective cohort study", Brain, 125, pp.765~772 (2002)
- Ha SW, "Risk Factors and Neuropsychological Characteristics According to Subtypes of Subcortical Ischemic Vascular Dementia: Preliminary Study", Dementia and Neurocognitive Disorders, 5, pp.63~69 (2006)
- Black S, "Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial", Stroke, 34, pp.2323~2330 (2003)
- Wilkinson D, "Donepezil in vascular dementia: a randomized, placebo- controlled study", Neurology, 61, pp.479~486 (2006)
- Orgogozo JM, "Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300)", Stroke, 33, pp.1834~1839 (2002)
- Wilcock G, "A double- blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM 500)", Int Clin Psychopharmacol, 17, pp.297~305 (2002)
- Erkinjuntti T, "Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial", Lancet, 359, pp.1283~1290 (2002)
- Auchus AP, "Galantamine treatment of vascular dementia: a randomized trial", Neurology, 69, pp.448~458 (2007)
- Erkinjuntti T, "Research criteria for subcortical vascular dementia in clinical trials", J Neural Transm Suppl, 59, pp.23~30 (2000)
- Kang Y, "A validity study on the Korean Mini- Mental State Examination (K-MMSE) in dementia patients", J Korean Neurol Assoc, 15, pp.300~308 (1997)
- Dodds TA, "A validation of the functional independence measurement and its performance among rehabilitation inpatients", Arch Phys Med Rehabil, 74, pp.531~536 (1993)
- Heinemann AW, "Relationships between impairment and physical disability as measured by the functional independence measure", Arch Phys Med Rehabil, 74, pp.566~573 (1993)
- Stern RA, "The Boston QualitativeScoring System for the Rey-Osterrieth Complex Figure: description and interrater reliability", Clin Neuropsychologist, 8, pp.309~322 (1944)
- Pohjasvaara T, "Clinical features of MRI-defined subcortical vascular disease", Alzheimer Dis Assoc Disord, 17, pp.236~242 (2003)
- Vinters HV, "Neuropathologic substrates of ischemic vascular dementia", J Neuropathol Exp Neurol, 60, pp.658~659 (2000)
- Gottfries CG, "The neurochemistry of vascular dementia", Dementia, 5, pp.163~167 (1994)
- Ballard C, "The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer’s disease", Int J Geriatr Psychiatry, 16, pp.499~503 (2001)
- Miyao S, "Leukoaraiosis in relation to prognosis for patients with lacunar infarction", Stroke, 23, pp.1434~1438 (1992)
- Clark CM, "Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer’s Disease", Arch Neurol, 56, pp.857~862 (1999)
- MölsäPK, "Survival and cause of death in Alzheimer’s disease and multi-infarct dementia", Acta Neurol Scand, 74, pp.103~107 (1986)
- Lopez OL, "Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease", J Neurol Neurosurg Psychiatry, 72, pp.310~314 (2002)
- Fazekas F, "Pathologic correlates of incidental MRI white matter signal hyperintensities", Neurology, 43, pp.1683~1689 (1993)
- Mungas D, "MRI predictors of cognition in subcortical ischemic vascular disease and Alzheimer’s disease", Neurology, 57, pp.2229~2235 (2001)
- Ballard C, "A review - Depression in dementia sufferers", Int J Geriatr Psychiatry, 11, pp.507~515 (1996)
- Ballard C, "Anxiety, depression and psychosis in vascular dementia: prevalence and associations", J Affect Disord, 59, pp.97~106 (2000)